ONT-093, also known as OC 144093, is primarily recognized for its role as a potent inhibitor of P-glycoprotein (P-gp), a protein that plays a significant role in multidrug resistance (MDR) in cancer cells. By inhibiting P-gp, ONT-093 enhances the intracellular accumulation of chemotherapeutic agents, thereby increasing their efficacy in treating drug-resistant cancers. This makes it a valuable adjunct in combination therapies, particularly for cancers that have developed resistance to standard treatments.

In addition to its application in oncology, ONT-093 has been explored for its potential to improve the bioavailability of various drugs that are substrates of P-gp. This includes enhancing the absorption and distribution of drugs across the blood-brain barrier, which can be particularly beneficial for treating neurological disorders where drug delivery is often a challenge.

Research has also indicated that ONT-093 may have utility in reversing multidrug resistance in infectious diseases, particularly in cases where pathogens have developed resistance to antimicrobial agents. By inhibiting efflux pumps similar to P-gp in bacteria, ONT-093 can potentially restore the effectiveness of antibiotics that have become less potent due to resistance mechanisms.

Overall, ONT-093's ability to modulate drug transport mechanisms makes it a promising candidate for improving therapeutic outcomes in various fields, including cancer treatment, neurology, and infectious disease management.